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Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the PTEN and TP53 tumor suppressor
genes. In contrast, however, most candidate tumor suppressors are part of large recurrent hemizygous deletions, such as the
common chromosome 16q deletion, which involves the AKT-suppressing phosphatase PHLPP2. Using RapidCaP, a genetically
engineered mouse model of Pten/Trp53 mutant metastatic prostate cancer, we found that complete loss of Phlpp2
paradoxically blocks prostate tumor growth and disease progression. Surprisingly, we find that Phlpp2 is essential for
supporting Myc, a key driver of lethal prostate cancer. Phlpp2 dephosphorylates threonine-58 of Myc, which renders it a
limiting positive regulator of Myc stability. Furthermore, we show that small-molecule inhibitors of PHLPP2 can suppress
MYC and kill PTEN mutant cells. Our findings reveal that the frequent hemizygous deletions on chromosome 16q present a
druggable vulnerability for targeting MYC protein through PHLPP2 phosphatase inhibitors.
Introduction
Prostate cancer (PC) is one of the most prevalent cancers among
men, causing almost 30,000 deaths in the United States alone.
Death is mainly due to metastasis, as the 5-yr survival rate of
metastatic PC is only 28%. In contrast, the 5-yr survival rate of
organ-confined disease is almost 99% (National Cancer Institute,
2016). Understanding how genetic alterations are linked to
cancer progression can help explain how tumor cells escape
from focal disease sites to distant metastatic sites. However,
there is a scarcity of human prostate metastatic samples for
research purposes because invasive biopsies at metastatic sites
can be dangerous and offer uncertain clinical benefit to patients.
Large-scale genomics efforts on both primary and metastatic
PC have transformed our basic understanding of the genetics
behind patient progression to metastatic disease. Two major
lessons learned from these collaborative studies can be sum-
marized as follows. First, PC has a low DNA missense mutation
rate (Lawrence et al., 2013), resulting in only a few recurrent
mutations (Barbieri et al., 2012) that show no increase in met-
astatic sample analysis (Robinson et al., 2015). In contrast, DNA
repair–associated mutations may offer new therapeutic oppor-
tunities (Grasso et al., 2012; Cancer Genome Atlas Research
Network, 2015; Mateo et al., 2015, 2017), but at this point they
cannot help to identify the bulk of men who are at risk of
progression. Second, metastatic patient samples reveal a sharp
increase in the number of recurrent DNA copy number alter-
ations (CNAs). These cover known drivers of disease, including
PTEN, TP53,MYC, RB1, and amplification of AR, which is induced
by hormone ablation therapy (Taylor et al., 2010; Cancer
Genome Atlas Research Network, 2015; Robinson et al., 2015).
However, most regions that suffer recurrent CNAs are still
awaiting rigorous validation of the candidate cancer genes that
they contain.
We, and others, use genetically engineered mice (GEMs) to
functionally test the contribution of individual gene alterations
to the disease (Irshad and Abate-Shen, 2013). Modeling of pri-
mary PC has demonstrated the pivotal role of Pten as an essential
suppressor of PI 3-kinase/Akt signaling in controlling onset,
progression, and outcome of the disease, either alone
(Podsypanina et al., 1999; Kwabi-Addo et al., 2001; Trotman
et al., 2003) or when combined with other insults (Di
Cristofano et al., 2001; Chen et al., 2005; Trotman et al., 2006;
Ding et al., 2011). Of particular relevance to this study, we have
previously shown that loss of the phospho-Akt inhibiting Phlpp1
phosphatase triggers prostatic neoplasia on its own, and when
combined with hemizygous loss of Pten results in highly pene-
trant prostate carcinoma (Chen et al., 2011). These results were
.............................................................................................................................................................................
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; 2Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell
Medicine, New York, NY; 3Department of Pharmacology, University of California San Diego, La Jolla, CA; 4Department of Pathology, University of Michigan, Ann Arbor, MI.
Correspondence to Lloyd C. Trotman: trotman@cshl.edu; Dawid G. Nowak: dgn2001@med.cornell.edu.
© 2019 Nowak et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the
publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0
International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
Rockefeller University Press https://doi.org/10.1083/jcb.201902048 1
J. Cell Biol. 2019
on May 29, 2019jcb.rupress.org Downloaded from 
http://doi.org/10.1083/jcb.201902048Published Online: 15 May, 2019 | Supp Info: 
consistent with the notion that the degree of PI 3-kinase/Akt
pathway activation dictates disease course (Trotman et al.,
2003), a notion that long served as the blueprint for target
therapy of PC (Majumder and Sellers, 2005).
To now explore the mechanisms behind metastasis, we have
recently developed RapidCaP (Cho et al., 2014). In this GEM
model for analysis and therapy of endogenous metastatic PC, we
are using somatic gene transfer to trigger loss of Pten and Trp53
in prostate, two alterations that have emerged as a hallmark of
the human metastatic PC genome (Armenia et al., 2018). The
analysis of primary lesions and visceral metastases revealed a
surprise: in contrast to primary PC, suppression of Akt was seen
in metastasis (Cho et al., 2014; Nowak et al., 2015). Mechanis-
tically, we showed that inactivation of phospho-Akt was medi-
ated by its phosphatase, Phlpp2, consistent with high Phlpp2
expression in the phospho-Akt–negative metastatic lesions from
multiple histological sites (Nowak et al., 2015).
PHLPP2 and the closely related paralog PHLPP1 are members
of the protein phosphatase 2C (PP2C) family of Mg2+/Mn2+-de-
pendent phosphatases, which are insensitive to most common
phosphatase inhibitors, including okadaic acid (OA; Brognard
et al., 2007). They can inactivate signaling of their targets AKT
and PKC by dephosphorylation of the C-terminal hydrophobic
phosphorylation motifs (Brognard and Newton, 2008; Gao et al.,
2008).
Since Phlpp1 loss triggers PC initiation by activation of Akt
(Chen et al., 2011), but in metastasis we found that Akt is sup-
pressed by a mechanism that requires Phlpp2, it has become
unclear if Phlpp2 promotes or prevents the disease. Human PC
genomics does not provide strong clues, as PHLPP2 is part of a
recurrent broad hemizygous deletion in primary and metastatic
disease. Therefore, we used genetics to directly test the role of
Phlpp2 in vivo using the RapidCaP system as done previously for
other candidate cancer genes (Cho et al., 2015; Chen et al., 2017).
Our results show that despite its ability to suppress Akt kinase,
Phlpp2 is required for PC and its progression because it can de-
phosphorylate and stabilize the Myc oncogene. The frequent
hemizygous PHLPP2 deletions therefore make it an attractive
drug target.
Results
PHLPP2 maintains MYC levels and cell proliferation
To dissect mechanistic connections between genes of interest,
we first used in vitro recombination of mouse-derived primary
cells, as published recently (Nowak et al., 2015). This approach
allows us to dissect immediate mechanistic consequences of
gene deactivation(s) from adaptive long-term responses in tis-
sue culture (Fig. 1, A and B; and Fig. S1 A). Pten/Trp53 co-deletion
results in increased levels of total Myc and Phlpp2, consistent
with our previously published results (Nowak et al., 2015; Fig. 1
A and Fig. S1 B). In contrast to Phlpp2, Phlpp1 was not increased
in the PtenΔ/Δ;Trp53Δ/Δ double mutants relative to the Trp53Δ/Δ
single mutant, a consistent observation that was in line with our
earlier findings suggesting that cells modulate Phlpp2 rather
than Phlpp1 to compensate for Pten loss (Fig. 1 A; Chen et al.,
2011).
To assess the impact of Phlpp2 loss in double-mutant cells, we
generated and tested triple-mutant PtenΔ/Δ;Trp53Δ/Δ;Phlpp2Δ/Δ
mouse embryonic fibroblasts (MEFs). First, we noted a signifi-
cant drop in proliferation of these cells compared with the
double-mutant PtenΔ/Δ;Trp53Δ/Δ cells (Fig. 1 B, left panel). Protein
analysis revealed increases in Akt activation upon Phlpp2 loss, as
expected. To our surprise, however, we found that loss of Phlpp2
caused a sharp reduction in the total levels of Myc (Fig. 1 B, right
panel). MYC is a driver oncogene of many cancer types, in-
cluding human PC and classic GEMs of the disease (Ellwood-Yen
et al., 2003; Farrell and Sears, 2014; McKeown and Bradner,
2014; Fernandez-Salas et al., 2016). Notably, we found that
Myc is a spontaneously activated, essential driver of metastasis
and resistance to castration therapy in RapidCaP (Cho et al.,
2014; Nowak et al., 2015). Activation of the p16 tumor suppres-
sor was also seen in these cells (Fig. 1 B, right panel), a response
that can be overcome byMyc to cause immortalization (Gil et al.,
2005). In addition, Phlpp2 loss did not affect levels of Phlpp1,
showing lack of general compensation between these two pro-
teins (Fig. 1 B, right panel).
To explore the result on MYC suppression in more depth, we
next turned from simultaneous deletion of the three cancer
genes to spontaneous loss of PHLPP2 in a stable PTEN/TP53
mutant (cancer) cell background using CRISPR/Cas9 and siRNA.
Using the latter approach first in PtenΔ/Δ;Trp53Δ/Δ MEFs, we
confirmed suppression of Myc upon Phlpp2 knockout together
with increased phosphorylation of Akt (Fig. 1 C, upper left
panel). Functional analysis of these cells also showed decreased
proliferation after Phlpp2 deletion (Fig. 1 C, right panel). Con-
versely, overexpression of PHLPP2 in the double-mutant cells
caused an increase in Myc protein, confirming the notion that
PHLPP2 regulatesMyc levels (Fig. 1 C, lower left panel). Next, we
knocked down PHLPP2 in DU145 cells, a human metastatic PC
cell line. As shown in Fig. 1 D (left panel), PHLPP2 siRNA caused
an ∼75% reduction in MYC protein, as quantified by densito-
metric analysis (Fig. 1 D, right panel). PHLPP2-siRNA knock-
down in PC3, another PC metastatic cell line (Fig. 1 E, left panel),
also caused a reduction inMYC protein levels (by ∼40%; Fig. 1 E,
right panel).
Finally, we tested if genetic targeting of PHLPP2 can be used
to deplete DU145 cells upon stable infection with our anti–
PHLPP2-CRISPR-Cas9-P2A-VenusFP viral vector system (ECPV;
Chen et al., 2017; Senturk et al., 2017). Fig. 1 F shows how tar-
geting of PHLPP2 with two different guides efficiently depleted
the fluorescence-positive cells relative to the control. In con-
trast, the nonmetastatic cell line 22Rv1 showed no difference
after Phlpp2 targeting (Fig. 1 F and Fig. S1 C). Collectively, our
results suggested that PHLPP2 both controls and is required to
maintain MYC levels and proliferation of cells, possibly more
efficiently in metastatic cell lines.
PHLPP2 controls MYC stability
MYC up-regulation in human cancers occurs via a multitude of
mechanisms (see Discussion); we observed gene amplification in
metastatic and castration-resistant RapidCaP lesions (Cho et al.,
2014). MYC stability is regulated by an intriguing phosphoryl-
ation system involving two conserved residues. Phosphorylation
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Figure 1. Deletion of Phlpp2 suppresses proliferation of primary and cancer cells. (A) Analysis of signaling pathways by Western blot analysis of cell
lysates from different genotypes of primary MEFs. (B) Loss of the Phlpp2 gene causes primary MEFs to proliferate less aggressively when compared with the
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of Serine 62 (S62) by the kinases CDK2 (Hydbring et al., 2010),
extracellular signal–related kinase (ERK; Sears et al., 2000), or
CAMKIIγ (Gu et al., 2017) increases MYC stability (Fig. 2 A). In
contrast, phosphorylation of threonine-58 (T58) by GSK3β
triggers dephosphorylation of phospho-S62 by PP2A (Yeh et al.,
2004). This is followed by ubiquitination of MYC by the SCF-
Fbw7 E3 ligase and proteasomal degradation (Welcker et al.,
2004). MYC degradation takes place in the nucleolus because,
in the nucleoplasm, ubiquitination is counteracted by USP28, an
ubiquitin-specific protease. USP28 binds to MYC via an inter-
action with FBW7α (Popov et al., 2007). We therefore tested if
PHLPP2 affects phosphorylation of MYC and its stability as
outlined in Fig. 2 A.
Deletion of Phlpp2 clearly increased the steady-state phos-
phorylation ofMyc at T58 (Fig. 2 B), and PHLPP2 overexpression
led to decreased T58 phosphorylation (Fig. 2 C). OA is an in-
hibitor of PP2A to which the PP2C-type phosphatases, such as
PHLPP2, are insensitive (Gao et al., 2008). First, we observed
that the Phlpp2 knockout boosted T58 phosphorylation, but not
that of S62 (Fig. 2, D and E, lane 1 vs. 3). Second, Phlpp2 loss
lowered Myc total levels (Fig. 2 D, lane 1 vs. lane 3). Further-
more, we saw that treatment with OA boosts Myc phosphoryl-
ation on S62, but not T58 (Fig. 2, D and E; lane 1 vs. lane 2). These
results confirmed the previously proposed dominant role of T58
phosphorylation in dictatingMyc levels (Sears, 2004; Farrell and
Sears, 2014) and introduced Phlpp2 as a key regulator.
Based on our quantitative PCR results, we could exclude
transcriptional suppression ofMyc upon Phlpp2 knockout (Fig. 3
A). Instead, Myc protein was decreased by ∼75% on average
(Fig. 3 B). Note that, for example, p16/Ink4a was in contrast
increased at both protein and mRNA levels (Fig. 1 B and Fig. S2
A). Next, we studied Myc protein turnover as a function of
Phlpp2 status using cycloheximide. As shown in Fig. 3, C and D,
the Phlpp2-deficient MEFs consistently showed a reduced half-
life of Myc protein (see Fig. S2, B and C, for replicates at various
cycloheximide concentrations). Taken together, our results in-
troduced Phlpp2 as a regulator of Myc stability via regulation of
T58 phosphorylation.
PHLPP2 directly dephosphorylates Myc
To address whether PHLPP2 targets Myc directly, we first ex-
pressed HA-PHLPP2 in 293T cells. These lysates were then
mixed with lysates from the murine PC-derived MycCaP cells,
which express elevated levels of transgenic Myc (Watson et al.,
2005). Co-immunoprecipitation revealed that overexpressed
HA-PHLPP2 specifically pulled down the transgenic Myc,
consistent with a direct interaction (Fig. 4 A). We next examined
if PHLPP2 directly and selectively dephosphorylates the T58
residue on Myc. The purified FLAG-tagged PP2C domain of
PHLPP2 (Sierecki et al., 2010) was incubated with cell lysates
derived from Pten/Trp53/Phlpp2-negative cells, which present
well-detected levels of phosphorylated Myc at T58. As shown
(Fig. 4 B), this incubation resulted in strong dephosphorylation
of T58 (lane 3 vs. lane 4) that was effectively blocked by a
PHLPP2 inhibitor (lane 5 vs. lane 6). Similar results were ob-
tained when testing our positive control, the known regulation
of PKC by PHLPP2 (Fig. 4 B and Fig. S3 A). To test if PHLPP2 also
affects S62 of Myc, the purified FLAG-tagged PP2C domain of
PHLPP2 was incubated with cell lysates derived from OA-
treated, Pten/p53-deficient cells generating visibly phosphory-
latedMyc-S62 because of the PP2A inhibition. In contrast to T58,
however, this incubation did not result in dephosphorylation of
S62 (Fig. 4 C, lane 3 vs. lane 4), consistent with specific de-
phosphorylation of pMYCT58 by PHLPP2. Lambda phosphatase, a
broadly active serine–threonine phosphatase, was used as a
positive control for dephosphorylation in these assays (Fig. 4, B
and C, lane 7 vs. lane 8). The PP2C domain is mediating PHLPP1/
2 phosphatase activity, but the similarity between the paralogs is
only 57% at the amino acid level (Fig. 4 D and Fig. S3 B). We thus
also tested the kinetics of dephosphorylation by the PP2C do-
main of PHLPP1 and found that it did not cause dephosphoryl-
ation of pMYC at T58 (Fig. 4 D). Collectively, these results
strongly suggested that PHLPP2 directly dephosphorylates the
T58 site of MYC, but not S62.
Phosphorylation on T58 is a signal for MYC degradation (Sears
et al., 2000; Welcker et al., 2004), and the lymphoma-associated
T58A mutation of MYC has therefore enhanced oncogenicity
(Hemann et al., 2005). Based on our findings, MycT58A protein
levels should thus not be affected by Phlpp2 deletion. Indeed, as
shown in Fig. 4 E, we found thatMycT58A levelswere insensitive to
Phlpp2 deletion as we observed strong MycT58A expression under
conditions where we could not detect MycWT expression in the
Phlpp2-deficient cells (Fig. 4 E, see V5-Myc, right panels).
Pharmacological inhibition of Phlpp2 suppresses Myc
and proliferation
Based on the above findings, we next tested the intriguing hy-
pothesis that an inhibitor developed to target the PHLPP2 PP2C
domain could have an anticancer effect by suppressing MYC
protein, a key oncogene that cannot yet be pharmacologically
controlled. Various cell types were therefore treated with this
inhibitor (NCI45586; see Sierecki et al., 2010). First, we tested
Pten/Trp53-null cells (left panel). Error bars, SD; n ≥ 3; *, P < 0.05 with Student’s t test at days 4 and 6. Combined loss of the Pten/Trp53/Phlpp2 genes decreases
expression of Myc and increases p16 expression (right panel). (C)Western blot analysis confirms efficient knockout of Phlpp2with the CRISPR/Cas9 system and
a decrease in activation of Myc expression (left upper panel, lines indicate splicing of two irrelevant lanes). Guide 1 anti-Phlpp2 (g.1) suppresses proliferation of
Pten/Trp53–negative cells (right panel). Overexpression of PHLPP2 leads to increased Myc expression (lower left panel). Error bars, SD; n ≥ 3; *, P < 0.05 with
Student’s t test at days 2, 4, and 6. (D)Western blot analysis confirms knockdown of PHLPP2 in DU145-human PC cells with siRNA (left panel), reaching almost
75% efficiency after 72 h, as quantified by densitometric analysis (right panel). Error bars, SD; n = 2; *, P < 0.05 with Student’s t test. (E)Western blot analysis
confirms knockdown of PHLPP2 in PC3 human PC cells with siRNA (left panel), reaching almost 40% efficiency after 72 h, as quantified by densitometric
analysis (right panel). Error bars, SD; n = 2; *, P < 0.05 with Student’s t test. (F)Western blot analysis shows knockdown of PHLPP2 in DU145 cells with two
different guides (left panel). Depletion of the PHLPP2 mutant cells as seen by depletion of Venus-positive cells compared with g.Ren.Ctrl, normalized at day 4.
Error bars, SD; n = 4; ANOVA, Dunnett’s post hoc test; P < 0.05 versus g.Ren.Ctrl at each respective day. wt, wild-type.
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two GEM-derived cell lines, known to drive PC through Myc
(Watson et al., 2005; Cho et al., 2014). As expected, the Phlpp2
inhibitor induced a dose-dependent increase in phospho-S473 of
Akt in the PtenΔ/Δ;Trp53Δ/Δ cells (Fig. 5 A). Importantly, this was
accompanied by a dose-dependent reduction in total Myc pro-
tein, entirely consistent with our observations above. The mu-
rine PC-derived MycCaP cell line showed the same opposite
effects on Myc and Akt (Fig. 5 B) as well as an increase in cell
death (Fig. S3 C). We confirmed that the inhibitor also caused
cell death in our RapidCaP PC-derived RCaP cells (Naguib et al.,
2018; see Fig. S3 D) and that genetic ablation of Phlpp2 increased
cell death in MEFs (Fig. S3 E). These results strongly indicated
that Myc levels, rather than Akt activation, drive survival and
proliferation in the cells, a hierarchical relation that is consistent
with our previously published results in cells (Nowak et al.,
2015) and in mouse primary and metastatic PC (Cho et al., 2014).
Figure 2. Phlpp2 status controls phosphorylation of Myc. (A) Scheme representing regulators of MYC protein through T58 and S62 phosphorylation sites.
These sites can be phosphorylated by GSK3β and CDK1/ERK/CAMKIIγ, respectively. Note that decreased ratios of T58 to S62 phosphorylation and T58
mutation to non–phospho-mimetic residues (e.g., T58A) are recurrent in human cancer. (B) Phlpp2 knockout in Pten/Trp53-null MEFs increases phosphorylation
at the T58 site. Lines indicate splicing of three irrelevant lanes. (C) Overexpression of PHLPP2 leads to decreased T58 phosphorylation. (D) Treatment of Pten/
Trp53-null MEFs with OA results in an increase in Myc phosphorylation on S62, but not T58. Total levels of Myc were reduced upon deletion of Phlpp2.
(E) Densitometric analysis shows that the phosphorylation ratio of T58 to S62 is significantly increased in the triple-deleted MEFs. Data are presented as the
densitometric measurements of pMycT58 and MycS62 normalized to β-actin and then these ratios of pMycT58 to MycS62 were used in graph as fold to PtenΔ/Δ;
Trp53Δ/Δ DMSO. Error bars, SD; n = 5; one-way ANOVA, P values corrected for multicomparison testing using the two-stage linear step-up procedure of
Benjamini, Krieger, and Yekutieli, with a false discovery rate at 10%. *, P < 0.05. KO, knockout; ns, not significant.
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We next tested human PC cell lines. In the metastasis-
derived DU145 cells, NCI45586 also showed suppression of
MYC and some activation of AKT (Fig. 5 C; see Fig. S3 F for
replicates). Treatment with inhibitor led to decreased cell
viability and proliferation (Fig. 5 E), and it increased cell
death (Fig. 5 F). Similarly, in the bone metastasis–derived PC3
cells, the inhibitor caused suppression of MYC and a decrease
in cell viability, despite activation of AKT (Fig. 5, G–I; and Fig.
S3 G). Our results with the NCI45586 tool compound closely
mirrored those from genetic ablation of the PHLPP2 gene, a
proof of concept that could lead to development of pharma-
cologically relevant drugs. In summary, our results showed
that the PHLPP2 function of protecting MYC can be targeted
to kill PTEN mutant cells.
Deletion of Phlpp2 slows down primary tumor growth and
prevents progression to metastasis
Wehave recently developed RapidCaP, a GEMmodel for analysis
and therapy of endogenous metastatic PC (Cho et al., 2014). Of
note, we could show that metastasis to multiple organs can be
selectively targeted using JQ1 to transcriptionally suppress Myc.
Thus, we now used RapidCaP to test how ablation of Phlpp2
would affect disease (note that NCI45586 cannot be used in
mice). We generated conditional knockout mice (Phlpp2loxP/loxP)
and crossed them to the PtenloxP/loxP;Trp53loxP/loxP mice on
which RapidCaP is based to generate the novel triple-mutant
PtenloxP/loxP;Trp53loxP/loxP;Phlpp2loxP/loxP mice (Fig. S4, A and B).
Next, we used the RapidCaP system of intraprostatic Cre-
Luciferase virus delivery to generate a trial cohort of PtenΔ/Δ;
Figure 3. Phlpp2 status controlsMyc stability. (A)Myc transcript levels measured by quantitative PCR is not affected by genotype. Error bars, SD; n = 4; P >
0.05 with Student’s t test. (B) Myc protein is decreased in triple-mutant cells by almost 75%. Error bars, SD; n ≥ 7; ***, P < 0.001 with Student’s t test (left
panel). Right panel: Myc and Phlpp2 protein levels from WT, Pten/Trp53-, and Pten/Trp53/Phlpp2-negative cells. (C)Myc half-life as measured in MEFs of both
genotypes after treatment with 100 µg/ml of cycloheximide. (D) Quantification of Western blot shows significantly shortened half-life of Myc in triple-mutant
cells compared with the Phlpp2-positive cells. This graph represents densitometric analysis of Myc normalized with β-actin from the corresponding Western
blot in Fig. 3 C. Lines (blue: PtenΔ/Δ;Trp53Δ/Δ;Phlpp2Δ/Δ; and red: PtenΔ/Δ;Trp53Δ/Δ) represent the nonlinear regression model, using the one-phase exponential
decay curves. Myc half-life T1/2 was calculated based on this model, n = 1. Note that independent biological replicates are shown and quantified in Fig. S2, B and
C. ns, not significant; qPCR, quantitative PCR; wt, wild-type.
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Trp53Δ/Δ;Phlpp2Δ/Δ mice and compared their disease progression
and outcome to that of the PtenΔ/Δ;Trp53Δ/Δ RapidCaP mice. As
shown in Fig. 6 A, four out of five Pten/Trp53 double-mutant
mice presented with strong disease signals over a period of 10
mo. They also showed bioluminescent signal derived from me-
tastases that was clearly distant and distinct from the prostate-
derived signal seen in the lower abdomen. Kaplan-Meier
analysis of metastasis onset and outcome in the double-mutant
Figure 4. Phlpp2 dephosphorylates Myc directly. (A) Co-immunoprecipitation experiments revealed that overexpressed HA-tagged PHLPP2 pulled-down
transgenic (Tg) Myc (from MycCaP cells), consistent with a direct interaction. (B) PHLPP2 directly dephosphorylates T58 on Myc. Incubation with the FLAG-
tagged PHLPP2 PP2C domain (arrow) resulted in a decrease in T58 phosphorylation after 60 min of incubation (lanes 3 and 4). Dephosphorylation was blocked
by a small-molecule inhibitor of PHLPP2 (lanes 5 and 6). (C) PHLPP2 does not dephosphorylate S62 onMyc. Incubation with the FLAG-PP2C domain of PHLPP2
(arrow) did not affect S62 phosphorylation after 60 min of incubation (lanes 3 and 4). Dephosphorylation was not affected by a small-molecule inhibitor of
PHLPP2 (lanes 5 and 6). (D) The purified FLAG-tagged PP2C domain of PHLPP2 was incubated with phosphorylated purified Myc protein for different time
points. Incubation with the PP2C domain of PHLPP1 did not affect T58 even after 90 min. In contrast, incubation with the PP2C domain of PHLPP2 resulted in a
decrease in T58 phosphorylation that was most significant after 90 min. (E) MycT58A levels increase compared with WT MYC regardless of Phlpp2 demon-
strating that this site is key for Phlpp2-mediated Myc regulation. wt, wild-type.
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Figure 5. Small-molecule PHLPP2 inhibitors suppress MYC and trigger cell death. (A) Treatment with a PHLPP2 inhibitor decreases Myc expression and
increases pAktS473 activation in PtenΔ/Δ;Trp53Δ/Δ cells, compared with control DMSO treatment. (B) PHLPP2 inhibitor treatment results in decreased Myc
expression and increased Akt activation in the MycCaP murine PC cell line. Lines indicate splicing of three irrelevant lanes. (C) Treatment with the PHLPP2
inhibitor decreases Myc expression and increases pAktS473 activation in DU145 cells, compared with control DMSO treatment. (D) Relative cell viability of
DU145 cells upon PHLPP2 inhibitor treatment. The mean with error bars, SD (n = 6), and dose–response curves are plotted. IC50 values were derived from
curves fitted using a nonlinear regression model. (E) Treatment with the PHLPP2 inhibitor decreases cell numbers measured with crystal violet assays in DU145
cells, compared with control DMSO. ANOVA, Dunnett’s post hoc test; *, P < 0.05; ***, P < 0.001 versus control; error bars, SD; n = 4. (F) Treatment with the
PHLPP2 inhibitor increases cell death as shown by PI staining. ANOVA, Dunnett’s post hoc test; ***, P < 0.001 versus control; error bars, SD; n = 4. (G) PHLPP2
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mice (Fig. 6, A and B) showed overall kinetics that were very
similar to what we originally published (Cho et al., 2014). In
contrast, the cohort with Phlpp2 deletion showed significantly
reduced overall disease burden after a 10-mo follow up (Fig. 6,
A–C; PtenΔ/Δ;Trp53Δ/Δ;Phlpp2Δ/Δ). Yet, as seen in Fig. 6 C, quan-
tification showed an insignificant difference between the two
cohorts at 4 mo (P = 0.6, two-tailed Fisher’s exact test), dem-
onstrating the lack of metastatic progression potential of the
Phlpp2 mutant prostate tumors. Postmortem analysis of the
disease (Fig. 6 D) indicated metastasis to lymph nodes, liver, and
spleen, as previously described for RapidCaP (Cho et al., 2014),
but not in the triple-mutant animals (Fig. S4 C). Histological
examination of luciferase-positive lymph nodes allowed us to
identify the nests of large metastatic tumor cells with prominent
nucleoli and pale pleomorphic nuclei (Fig. 6 D, right panel, red
arrows) embedded within the lymphocytes. Note that total
sectioning of lymph nodes from the triple-mutant cohort did not
reveal any metastatic cells (data not shown).
Taken together, our in vivo genetic validation data demon-
strated that Phlpp2 is required for the tumor and metastasis
formation seen in the Pten/Trp53-mutant RapidCaP model.
Discussion
By activatingMYC and suppressing AKT, PHLPP2 exhibits a dual
nature in cancer. This may be reflected in its cancer-associated
alteration patterns, which are dictated by broad chromosomal
16q hemizygous deletions and some amplifications, as shown in
Fig. S5 A. Also, in PC, the vast majority of PHLPP2mutations are
broad 16q deletions (Fig. S5 B), which may result in some AKT
activation, as we have shown for Phlpp1 loss (Chen et al., 2011).
Yet, the remaining allele is widely retained in human PC me-
tastasis (Fig. S5 C) and clearly necessary to obtain metastasis in
RapidCaP, as shown above. This requirement for the retention of
one allele has been recognized as a druggable vulnerability of
cancer (“Cyclops” genes; Nijhawan et al., 2012). Indeed, an un-
biased analysis of such Cyclops gene candidates from human
cancer data did include PHLPP2 (see Table S3 in Nijhawan et al.,
2012). Thus, PHLPP2 could fall into a new type of category of
cancer genes. Its hemizygous loss can promote cancer through
AKT activation. The remaining allele, however, is protected
because it mediates survival through MYC. Thus, PHLPP2 is in a
unique position to regulate the signaling plasticity of a cell and
its switching between AKT (epithelial) andMYC (mesenchymal)
phenotypes. This switch can be observed in primary PC, and it
can drive Pten-deficient metastasis (Cho et al., 2014; Nowak
et al., 2015). It is intriguing to speculate that these opposing
activities may be achieved by regulation of PHLPP2 pools in the
nucleus (MYC) and the cytoplasm (AKT).
Several independent studies have now confirmed the exis-
tence of a Pten-null Akt-off state in PC (Ku et al., 2017; Zou et al.,
2017). In humans, the modeling of “AR indifference” by
pharmaco-genetic AR suppression of the PTEN-deficient LNCaP
cell line (Bluemn et al., 2017) revealed that the derived AR-
negative, ADT (androgen deprivation therapy)-resistant cells
no longer showed detectable AKT pathway activity despite PTEN
deficiency, closely mirroring our findings in RapidCaP mice,
especially after castration. Collectively, these results highlight
the importance of understanding AKT-negative, PTEN-deficient
disease, as it appears to be among the drivers of resistance to the
latest generation of androgen deprivation therapy.
It is estimated that 450,000 Americans are diagnosed each
year with a cancer that is driven by MYC (McKeown and
Bradner, 2014). MYC is a validated driver of PC in GEM mod-
els of primary disease and metastasis (Ellwood-Yen et al., 2003;
Cho et al., 2014). To date, there is no drug that directly targets
MYC because inhibitor design is limited by the lack of good
target motifs or clefts (McKeown and Bradner, 2014). Yet, sev-
eral indirect strategies have shown promise. Foremost among
them is inhibition at the level of transcription using inhibitors of
BRD4, such as the small molecule JQ1 (Delmore et al., 2011). This
approach has shownmuch promise in GEMmodels of, for example,
leukemia (Zuber et al., 2011), metastatic PC (Cho et al., 2014), lung
cancer, and neuroblastoma (Puissant et al., 2013; Shimamura et al.,
2013). This strategy is now the basis for several clinical trials (Liu
et al., 2017). Other approaches target upstream activators of MYC,
such as NOTCH1 (Weng et al., 2006), or interfere with MYC sta-
bility through indirect activation of PP2A. Activation of PP2A,
however, presents a formidable challenge because it (1) requires
indirect suppression of its endogenous inhibitors (Janghorban et al.,
2014; Kaur and Westermarck, 2016), (2) forms over 70 active hol-
oenzyme complexes, and thus (3) is known to control many pro-
teins and processes (Sangodkar et al., 2016).
We show that PHLPP2 protects MYC from degradation.
PHLPP2 dephosphorylates the T58 site of MYC, thus directly
increasing its stability (see model in Fig. 7). This residue suffers
recurrent mutation (T58A) in patients with Burkitt’s lymphoma,
and it was shown to cause increased transformation in vitro and
lymphoma in vivo (Chang et al., 2000; Hemann et al., 2005). The
T58A mutant is constitutively dephosphorylated, mimicking
constant PHLPP2 activity. Thus, its natural selection in MYC-
driven human lymphoma impressively demonstrates the onco-
genic power of PHLPP2 action on MYC.
Small-molecule inhibitors of PHLPP2 have been discovered
(Sierecki et al., 2010).We show that they can be used to suppress
MYC and cause cell death. The compounds were screened from
the First Diversity Set of the National Cancer Institute, which
comprises 1990 small molecules. At this stage, they should be
considered proof of principle compounds, rather than drugs.
This suggests, however, that targeted efforts for designing
PHLPP2 inhibitors could result in very efficient new drugs that
suppress MYC-driven cancer (see proposed model, Fig. 7).
The PHLPP2 phosphatase is an attractive drug target for
several reasons. First, we show that Pten-deficient metastatic PC
inhibitor treatment suppresses Myc and activates Akt in the PC3 human metastatic PC cell line. (H) Relative cell viability of PC3 cells upon PHLPP2 inhibitor
treatment. The mean ± SD (n = 3) and dose–response curves are plotted. IC50 values were derived from curves fitted using a nonlinear regression model using.
(I) Treatment with the PHLPP2 inhibitor increases cell death as shown by the PI-positive cell fraction. ANOVA, Dunnett’s post hoc test; ***, P < 0.001 versus
control; error bars, SD; n = 4.
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cells fully depend on it. In contrast, normal cells do not, as
demonstrated by the normal viability of the Phlpp2 knockout
mice (Wen et al., 2015). Next, general advances in structural
understanding of phosphatases have led to a “renaissance” of
inhibitor design (Krishnan et al., 2014; Chen et al., 2016). By
looking beyond the active site, novel allosteric inhibitors can
now shut down phosphatases that used to be considered “un-
druggable.” This could also apply to the PP2C-type active site of
PHLPP2. Thus, our work introduces the PHLPP2 phosphatase as
an unexpected, yet druggable, driver of MYC-driven PC and its
progression.
Materials and methods
Mice
PtenloxP/loxP;Trp53loxP/loxP and PtenloxP/loxP;Trp53loxP/loxP;
Phlpp2loxP/loxP were used in this study. All protocols for mouse
experiments were done in accordance with the institutional
guidelines and approved by Institutional Animal Care and Use
Committee. For the creating of Phlpp2loxP/loxP animals, we used
embryonic stem cells that were received from the Mouse
Phenotype Consortium (Phlpp2-IKMC Project: 47191). We used
promoter-driven targeting cassettes for the generation of a
“knockout-first allele” in C57BL/6N mice. First, mice were bred
to a flipase (Flp) mouse to remove lacZ/loxP/neo cassette that
gave a rise to loxP conditional mice. Following removal of the
floxed region using Cre, our expression analysis confirmed
knockouts of Phlpp2 at the protein level. PtenloxP/loxP;Trp53loxP/loxP,
PtenloxP/loxP;Trp53loxP/loxP, and Phlpp2loxP/loxP transgenic mice
were generated by crossing PtenloxP/loxP;Trp53loxP/loxP and
Phlpp2loxP/loxP. For genotyping, PCR of tail DNA was used with
the following primers: for PtenloxP/loxP, primer 1 (59-TGTTTT
TGACCAATTAAAGTAGGCTGTG-39) and primer 2 (59-AAAAGT
TCCCCTGCTGATGATTTGT-39) were used; for Trp53loxP/loxP,
primer 1 (59-CACAAAAACAGGTTAAACCCAG-39) and primer
2 (59-AGCACATAGGAGGCAGAGAC-39) were used; and for
Phlpp2loxP/loxP, primer 1 (59-GATGCTCTGCTTCTGCTCCTGTGC-39)
and primer 2 (59-GATATGAGGAACGAAGCAATATGGG-39)
were used.
MEFs
Animals with different combinations of loxP alleles were used.
At 13.5 d, embryos were harvested by sacrificing a female using
CO2. Embryos were minced and trypsinized for 15 min in a 37°C
water bath. Cells were plated on a 10-cm dish and cultured in
10% DMEM and 1× penicillin–streptomycin. 72 h after plating,
cells were split into a 10-cm dish at 900,000 cells per dish per
15-ml volume of 10% DMEM and 1× penicillin–streptomycin.
Cells were cultured for the next 3 d, collected, frozen in 20%
dimethyl sulfoxide/80% FBS, and stored in batches of 1,000,000
cells per cryovial in liquid nitrogen. All protocols for mouse
experiments were conducted in accordance with the institu-
tional guidelines and were approved by the Institutional Animal
Care and Use Committee at Cold Spring Harbor Laboratory
(protocol number 562709, “Tumor suppressor mutation in
mouse models for cancer”).
Cancer cell lines
Cell lines were used and cultured in 10% DMEM (MycCaP) or
RPMI (PC3, DU45) medium and 1× penicillin–streptomycin.
Drug treatments on 2D cell lines and propidium iodide analysis
For PHLPP2 inhibitor experiments, the NCI45586 compound
was used to assess effects of PHLPP2 on pAkt, Myc signaling, and
cell death measured with propidium iodide (PI) using Guava
easyCyte 8HT Benchtop Flow Cytometer (Millipore Sigma). The
PHLPP2 inhibitor was resuspended in DMSO and used as pre-
viously described (Sierecki et al., 2010).
Drug treatment on 3D cultured RapidCaP-derived prostate
epithelial cells
3D cultures of a RapidCaP-derived prostate cell line was per-
formed as per the protocol in Drost et al. (2016). Matrigel was
Figure 6. Phlpp2is required for progression of Pten mutant PC. (A) Comparison of PC progression to metastasis in double- and triple-mutant RapidCaP
mice as determined by bioluminescent (BLI) imaging. In the PtenΔ/Δ;Trp53Δ/Δ system, four out of five animals present with primary and metastatic signal within
10 mo, while little to insignificant disease is imaged in PtenΔ/Δ;Trp53Δ/Δ;Phlpp2Δ/Δ. (B) Kaplan–Meier analysis shows the early onset of metastasis in PtenΔΔ/Δ;
Trp53Δ/Δ compared with PtenΔ/Δ;Trp53Δ/Δ;Phlpp2Δ/Δ mice as determined by monthly luciferase imaging. P = 0.0042 with log-rank (Mantel-Cox) test; PtenΔ/Δ;
Trp53Δ/Δ: n = 5; PtenΔ/Δ;Trp53Δ/Δ;Phlpp2Δ/Δ: n = 16. (C) Bioluminescent signals are significantly lowered in PtenΔ/Δ;Trp53Δ/Δ;Phlpp2Δ/Δ animals compared with
PtenΔ/Δ;Trp53Δ/Δ mice at 10 mo but not at 4 mo (P = 0.6, two-tailed Student’s t test). Each dot represents bioluminescent (BLI) signal from one animal, lines are
means, and indicated P values are for two-tailed Student’s t tests. PtenΔ/Δ;Trp53Δ/Δ: n = 5; PtenΔ/Δ;Trp53Δ/Δ;Phlpp2Δ/Δ: n = 16. (D) Postmortem luciferase analysis
confirms metastasis to secondary organs in PtenΔ/Δ;Trp53Δ/Δ (left panels). The right panel shows a typical nest of prostate tumor cells having metastasized to
the luciferase-positive lymph node shown in the left panel. White asterisks indicate normal lymphocytes, and red arrows indicate metastatic prostate tumor
cells. Scale bar, 20 µm.
Figure 7. Proposed model for PHLPP2. PHLPP2 protects MYC from deg-
radation resulting in PC progression. PHLPP2 dephosphorylates the T58 site
of MYC, thus directly increasing its stability. Small-molecule inhibitors of
PHLPP2 have been discovered (Sierecki et al., 2010). PHLPP2 thus has op-
posing roles in PC: while suppressing AKT activation, it stabilizes MYC pro-
gression. Our data suggest that the latter function is critical for PC
progression.
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thawed overnight at 4°C and placed on ice during the experi-
ment. Prechilled glass-bottom 6-well plates were coated with a
thin layer of Matrigel (5 µl) and incubated for 30 min at 37°C to
allow the Matrigel to set. Cells (80% confluent) were harvested
to a single-cell suspension by trypsinization. Approximately
15,000 cells were aliquoted into a 1.5-ml microcentrifuge tube,
pelleted, and resuspended in 100 µl of Matrigel. The mixture of
cells and Matrigel was gently mixed. Three 30-µl aliquots of the
mixture was carefully overlaid onto the precoated surface of the
glass plate and allowed to set for 15 min at 37°C. Once the Ma-
trigel had set, cell culturemediawas carefully added to the wells.
The culture was maintained for 5 d before drug treatment and
media changed every 2 d. For drug treatment, 1 ml of fresh basal
media with vehicle or drug was added to overnight serum-
starved cells. 72 h after treatment, media were removed and
cells were extracted from Matrigel and dissociated for cell via-
bility analysis using trypan blue dye.
RNA isolation and quantitative RT-PCR
Isolation of RNA was performed using TRIzol (Invitrogen) and
purified by precipitation with isopropanol. Total RNA was re-
verse transcribed using the High Capacity cDNA Reverse Tran-
scription Kit (Life Technologies) according to themanufacturer’s
indications. 2 μl of this cDNA was then amplified by real-time
PCR in a final volume of 10 μl per reaction on a StepOnePlus
System thermocycler using the respective assays (Life Tech-
nologies). All reactions were performed in triplicate. The rela-
tive expression ofMyc, p16, and Phlpp2was determined using the
mean value of the control samples (WT) as calibrator and fol-
lowing the 2-ΔΔCt method.
Western blotting
To asses protein expression, we used SDS-PAGE (8% and 10%
reducing gels, 5% 2-β mercaptoethanol). Gels were loaded with
20–40 μg protein per well (Bradford assay). The following an-
tibodies were used: β-actin (1:30,000; Sigma-Aldrich), pAKT
(S473; 193H12, 1:3,000; Cell Signaling Technology), total AKT
(40D4, 1:3,000; Cell Signaling Technology), c-Myc (ab32072; 1:
3,000; Abcam), pMYC (T58; ab28842, 1:1,000; Abcam), pMYC
(S62; E1J4K, 1:1,000; Cell Signaling Technology), proliferating
cell nuclear antigen (PCNA) (PC10, 1:6,000; Santa Cruz Bio-
technology), PTEN (6H2.1; 1:1,000; Cascade Bioscience), p16
(M-156; 1:1,000; Santa Cruz Biotechnology), PHLPP2 (A300-661A;
1:1,000), and V5-tag (#13202, 1:1,000; Cell Signaling Technology).
ECL was used with Amersham Hyperfilm ECL (Amersham Bio-
science) combined with signal intensity analysis using the Im-
ageJ 1.38× software. Infrared-based recording and quantification
were done using the LiCor Odyssey Classic infrared scanner and
Image Studio Lite software version 5.2. Histogram analysis was
done to prevent pixel saturation and clipping.
MTT assays
10,000 cells/well were seeded in full media (RPMI, 10% FBS) on
a 96-well plate and left to adhere overnight. The cells were se-
rum starved (RPMI, 0% FBS) for 24 h. After serum starvation,
the cells were treated with an eight-point twofold dilution of the
Phlpp2 inhibitor (compound #13) in 2% FBS-RPMI for 96 h. After
treatment, the medium containing the compound was removed
and MTT solution was added. After labeling cells with MTT, the
absorbance was read at 570 nM.
Crystal violet assay
Cell proliferation was also measured using the crystal violet
method as previously described (Nowak et al., 2015). Cells were
fixed in 10% formalin for 15 min, washed with sterile water, and
stained with 0.1% crystal violet solution. Solutions were aspi-
rated and washed with water, and then plates were air dried
overnight. After this, 10% acetic acid was added and mixed with
water in a 1:3 ratio. Absorbance was measured at 590 nm using a
plate reader (Synergy H4 Hybrid Multi-Mode Microplate
Reader; Biotek).
Myc mutant transfection
PtenloxP/loxP;Trp53loxP/loxP and PtenloxP/loxP;Trp53loxP/loxP;
Phlpp2loxP/loxP cells previously infected with adenovirus carrying
Cre recombinase were seeded in the full media (DMEM, 10%
FBS) on a 6-well plate and left to adhere overnight. Cells then
were transfected with plasmids: pD40-His/V5-c-Myc (Addgene;
#45597) and pD40-His/V5-c-MycT58A (Addgene; #45598; Yeh
et al., 2004) using Lipofectamine 2000 following the manu-
facturer’s protocol (Thermo Fisher Scientific; 11668027). 16 h
after transfection, cells were analyzed using Western blots.
siRNAi transfection targeting PHLPP2
PC3 and DU145 cells were transfected with siRNAi control (ON-
TARGETplus Non-targeting Pool; Darmacon) and siRNAi targeting
PHLPP2 (ON-TARGETplus Human PHLPP2; Darmacon) using
DharmaFECT following the manufacturer’s protocol. 48–72 h after
transfection, cells were analyzed using Western blots.
Immunoprecipitation
DNA was transfected into HEK-293T cells using FuGene6
(Roche). Cells were collected 24 h after transfection and then
lysed in a buffer containing 50 mM Na2HPO4 (pH 7.5), 1 mM
sodium pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA,
1% SDS, 1 mMDTT, 1 µMmicrocystin, 20 µM bezamidine, 40 µg/
ml leupeptin, and 1 mM PMSF and then were sonicated briefly.
For co-immunoprecipitation, cells were lysed and the detergent-
solubilized cell lysates were incubated with an anti-HA antibody
(BioLegend; #901503) at 4°C overnight. The next day, the sam-
ples were incubated with protein A/G PLUS-Agarose (Santa
Cruz Biotechnology; #sc-2003) for 1 h at 4°C and then washed
three times in lysis buffer containing 0.05 M NaCl and 0.25%
Triton-X. Bound proteins and lysates were separated by
SDS-PAGE gel and analyzed by Western blotting.
Phosphatase assays
A 3XFLAG-tagged protein PHLPP2-PP2C was expressed in HEK-
293T cells and purified using anti-FLAG M2 affinity gel (Sigma-
Aldrich; A2220). The FLAG-PP2C protein was eluted from the
beads in elution buffer containing 50 mM Hepes, pH 7.4,
100 mM NaCl, 1 mM DTT, 0.1 mM Na3VO4, 0.01% NP-40, 10%
glycerol, and 0.5 mg/ml 3XFLAG peptide (Sigma-Aldrich;
F4799). Recombinant human Myc protein was purchased from
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Abcam (ab169901). To obtain phosphorylated Myc as substrate,
in vitro kinase assays were performed by incubating cMyc
(0.30 µM) with recombinant human GSK3 β (54.79 nM;
ab60863; Abcam) at 30°C for 15 min. Reactions were stopped
using 40 µM staurosporine (Calbiochem). The dephosphoryla-
tion reactions were performed with 3XFLAG-PP2C (0.76 µM)
and phosphorylated cMyc (0.30 µM) as a substrate in a reaction
buffer containing 50 mM Tris (pH 7.4), 1 mM DTT, and 5 mM
MnCl2 at 30°C for 0–90 min.
Lentivirus production
293FT cells were plated at a density of 400,000 cells/ml in the
volume of 27ml per 15-cm dish. The next day, target DNA (27 μg)
was combined with packaging constructs, 8 μg of pMD2.G and
20 µg of psPAX2, and 2 mol/liter calcium chloride. The mixture
was then added dropwise to cells that were treated with 6.7 μl
100 mmol/liter chloroquine. Medium was changed after 14 h,
and viral supernatants were collected 72 h after transfection.
Supernatants were then centrifuged and filtered with a 0.45-μm
filter before infection of cells. The 293FT cells were bought from
Thermo Fisher Scientific (R70007).
Lentivirus CRISPR/Cas9 experiments
gRNA were designed using the R package CRISPRseek (Zhu
et al., 2014). The highest-ranking gRNAs were chosen. The
gRNA oligonucleotides were purchased from Sigma-Aldrich and
phosphorylated and annealed according to previously published
protocols (Chen et al., 2017). The duplex oligonucleotides were
subsequently cloned into the lentiCRISPR_V2 plasmid (Addgene
Plasmid #52961) or ECPV vector (Senturk et al., 2017), replacing
the 2-kb filler.
Virus for mouse injections
The Luc.Cre lentiviral plasmid for mice injections was purchased
from Tyler Jacks (Koch Institute for Integrative Cancer Research,
MIT; Addgene plasmid #20905). The lentivirus was packaged and
purchased from the University of Iowa’s Viral Vector Core.
Intraprostate injection
Prior to surgery, the lower half of the mouse abdomen was
shaved. The mouse was given 2% isoflurane for the duration of
the 15-min procedure. Once deep anesthesia was determined,
the abdomen was cleaned with betadine and ethanol twice be-
fore the incision was made. A 1.5-cm incision was made through
the skin and the peritoneum to the right of the center abdomen.
The seminal vesicle and the anterior prostate were removed
and injected with 20 μl of lentivirus using a 30-gauge insulin
syringe. The peritoneum incision was sutured with dissolvable
sutures, and the skin incision was closed with steel EZ clips. The
mouse was laid on a warmed cage, allowed to fully recover, and
given DietGel. Lidocaine and buprenorphine were provided for
pain management.
Bioluminescence imaging and tissue histology
For all bioluminescent imaging, a Xenogen IVIS Spectrum was
used. For live imaging, animals were injected intraperitoneally
with 200 mg/kg of luciferin (D-luciferin, potassium salt; Gold
Biotechnology). 3 min after injection, animals were put under
2% isoflurane. At 10 min after luciferin administration, the an-
imals were transferred to the warmed camera stage and placed
in a nose cone with continuous 2% isoflurane. Animals were
scanned for 3 min and then removed from the camera and re-
covered in cages. For postmortem imaging, animals were hu-
manely sacrificed using CO2. The body of the animal was opened
up and luciferin was dropped throughout the body and scanned
for 3 min in the IVIS Spectrum. After all organs of interest were
also removed, luciferin was applied to the organs and scanned
for 3 min. For histology analysis, tissue was dissected from the
animal and placed in 10% buffered formalin. Tissues were fixed
for 24 h, followed by gentle wash and transfer to PBS. After
paraffin embedding the tissue was total sectioned at 5-µm
thickness and placed on charged glass slides. Every 10th sec-
tion was stained with hematoxylin and eosin to locate tumor
cells. Histology imaging was done at RT on an Axioplan micro-
scope (Zeiss) using a Zeiss 40× A-plan objective (Air; NA = 0.65)
and recorded on a Spot Flex 15.2, 64-Mp Shifting Pixel camera
and the Spot software version 5.2.
Data analysis
Graph analyses were performed using the R programming lan-
guage and ggplot2 package on Apple Macintosh computers.
Values are expressed as the means with SDs unless otherwise
stated. To compare two groups, Student’s t test was used, and P <
0.05 was considered statistically significant. For multiple com-
parisons, statistical analyses were performed on raw data using
the one-way ANOVA test (Dunnett’s post-test) or the one-way
ANOVA, with P values corrected for multicomparison testing
using the two-stage linear step-up procedure of Benjamini,
Krieger, and Yekutieli, with a false discovery rate at 10% using
GraphPad Prism 7. P < 0.05 was considered statistically signif-
icant. IC50 values were derived from curves fitted using a
nonlinear regression model using GraphPad Prism 7. See Table
S1 for a list of key resources.
Online supplemental material
Fig. S1 shows the mechanism of interaction between Akt and
Myc. Fig. S2 shows how Phlpp2 status affects Myc stability. Fig.
S3 presents an in vitro analysis of Phlpp2 activity and stability.
Fig. S4 shows modeling of Phlpp2 deletion in RapidCaP. Fig. S5
shows that hemizygous, not complete loss of PHLPP2, is common
in advanced PC patients. Table S1 shows a list of key resources.
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